Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF5993 vs Seretide in uncontrolled adolescent asthma
2024-514248-95-00Phase 3Authorised
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of beclometasone dipropionate/formoterol fumarate/glycopyrronium in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in pre-dose FEV1 at Week 26. Planned start Sep 2025; status: authorised.
02
Drugs
beclometasone dipropionate/formoterol fumarate/glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2024-514248-95-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514248-95-00.